How old do you have to be for peptides? What the law and the labels say

The short answer

There is no federal minimum age for peptides. The obesity and diabetes peptides carry an age on their label: 2 for Imcivree, 10 for Mounjaro, 12 for Wegovy and Saxenda, always under a prescriber. New York bars weight-loss and muscle-building supplements to under-18s. Research-labelled vials carry no age because nobody is supposed to be taking them.

Ask a search engine how old you have to be to buy peptides and you get three different kinds of answer, because there are three different kinds of product hiding under one word. A peptide is a short chain of amino acids, the same building blocks your body uses to make proteins, and in United States law that chemistry buys you nothing: what matters is the box the product is sold in. Some peptides are prescription drugs, and for those the age is written on the approved label and enforced by a prescriber [4] [5]. Some products are dietary supplements, and for those one state has now set an age of 18 [1]. And much of what is sold online is labelled "for research only" and "not for human use" [16], a category with no age on it at all, because the label is a claim that no human is going to take it.

So the honest short answer is that the number depends on which box you are looking at. Among the approved weight and blood-sugar peptides, the youngest label ages are 2, 10 and 12, each tied to a specific diagnosis and a specific clinical trial [5] [6] [7] [8]. For the vials sold as research chemicals, the "18+" you see on a checkout page is a contract term set by the seller, not a rule set by a drug regulator. The rest of this article walks through each box, copies the numbers off the actual labels and statutes, and ends with what that means for a teenager, a parent, or an adult who wants to know where the line is.

Where the number 18 actually comes from

Eighteen is the age of majority in most US states, the point at which a person can sign a binding contract. That is why vendor checkout pages say 18+. New York has turned it into a statute, and that law covers supplements marketed for weight loss or muscle building, not injectables sold as research.

The 18 that appears on peptide vendors' terms of service is not a drug law. It is the age of majority, the age at which the law treats you as an adult who can sign a contract and be held to it [3]. Most states set it at 18, but Alabama and Nebraska set it at 19 and Mississippi at 21 [3]. A seller who says "you must be 18 to order" is protecting the sale as a contract, nothing more. Peptides Academy itself is an adults-only platform for the same reason, and because the subject matter covers prescription medicines and unapproved compounds.

One state has gone further and written the age into law, and it is worth reading closely. New York's General Business Law section 391-oo says that no person or company "shall sell or offer to sell or give away" an over-the-counter diet pill or a dietary supplement for weight loss or muscle building to anyone under eighteen years of age, and requires retailers to demand proof of age [1]. Online sellers shipping into the state must use a delivery method that requires an adult of at least 18 to sign for the package and show government-issued photo identification at the door [1]. The penalty is modest: a court may impose a civil penalty of not more than five hundred dollars per violation, plus an injunction [1]. The supplement industry sued, and on 13 November 2025 the Second Circuit refused to pause enforcement while the case continues [2].

Now the limit of that law, which is where the peptide question gets interesting. The statute defines its target as a dietary supplement or diet pill that is "labeled, marketed, or otherwise represented for the purpose of achieving weight loss or muscle building" [1]. That definition names no ingredient. A vial of BPC-157 or a growth-hormone secretagogue sold with a "not for human use" sticker does not call itself a dietary supplement, so as far as we can read that definition, the age check the statute created never reaches it [1]. New York drew its line around the products with honest labels.

Prescription peptides are the only ones with an age written down

Federal law says a prescription drug may be dispensed only on the order of a licensed practitioner, and sets no patient age of its own. The age lives on each approved label: Wegovy and Saxenda at 12 for obesity, Mounjaro at 10 for type 2 diabetes, each backed by a named pediatric trial.

Semaglutide, liraglutide and tirzepatide are peptides, and in their branded forms they are also prescription drugs [5] [6] [7]. The federal rule for that category is short: a drug that is unsafe to use without a practitioner's supervision "shall be dispensed only upon a written prescription of a practitioner licensed by law to administer such drug", or an oral prescription promptly written down by the pharmacist [4]. That sentence sets no age. The age is in the approved label, which tells the prescriber which patients the evidence covers.

For weight, the label age is twelve. Wegovy (semaglutide) is indicated to reduce excess body weight in "adults and pediatric patients aged 12 years and older with obesity" [5]. That sentence rests on a single trial, a 68-week, double-blind, placebo-controlled study in 201 pubertal patients aged 12 and older with a body mass index (BMI, weight adjusted for height) at or above the 95th percentile for their age and sex; mean age was 15 and mean baseline weight was 108 kg [5]. After 68 weeks BMI fell 16.1 percent on semaglutide against a 0.6 percent rise on placebo, and 77.1 percent of treated patients lost at least 5 percent of their baseline BMI compared with 19.7 percent on placebo [5]. The published trial report gives the same headline result, with 180 of the 201 randomised participants completing treatment [9]. Saxenda (liraglutide, a once-daily injection) carries the same age with an extra condition: pediatric patients aged 12 and older with body weight greater than 60 kg and obesity, supported by a 56-week trial in 251 patients aged 12 to 17 [6].

For blood sugar, the label age is ten. Mounjaro (tirzepatide) is indicated to improve glycemic control in "adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus", on the strength of a 30-week placebo-controlled trial in 99 pediatric patients with a 22-week open-label extension [7]. In that trial, called SURPASS-PEDS, participants had a mean age of 14.7 and HbA1c (a three-month average of blood sugar) fell by a mean of 2.23 percentage points on pooled tirzepatide against a 0.05-point rise on placebo [12]. Two details matter for anyone reading that as permission: the pediatric maximum dose is 10 mg once weekly, lower than the adult 15 mg, and the indication is diabetes, not weight [7].

The youngest age among the obesity peptides is two

Among the peptides approved for obesity, the youngest label age belongs to Imcivree (setmelanotide): 2 for obesity caused by specific rare gene defects or Bardet-Biedl syndrome, and 4 for hypothalamic obesity after brain injury. The label explicitly excludes ordinary obesity. Age on a label always comes attached to a diagnosis.

Of the four labels in this article, the lowest age belongs to a peptide most people have never heard of: Imcivree (setmelanotide), an eight-amino-acid cyclic peptide, a synthetic cousin of the natural hormone alpha-MSH, that switches on the melanocortin 4 receptor in the brain's appetite circuitry [8]. (Other pediatric peptide drugs have their own labels and ages.) Its label allows use in patients aged 2 years and older whose obesity is caused by confirmed variants in the POMC, PCSK1 or LEPR genes or by Bardet-Biedl syndrome, and in patients aged 4 years and older with acquired hypothalamic obesity, the weight gain that follows damage to the hypothalamus, typically from a brain tumour or its treatment [8]. The hypothalamic indication rests on a placebo-controlled trial of 56 to 60 weeks that included 76 pediatric patients aged 4 to 17 [8].

The same label is unusually blunt about who it is not for. Under "Limitations of Use" it states that Imcivree is not indicated for, and would not be expected to be effective in, "other types of obesity not related to acquired HO, BBS or POMC, PCSK1 or LEPR deficiency, including obesity associated with other genetic syndromes and general (polygenic) obesity" [8]. That is the pattern to take away from every label in this article. An age on a label is never a free-standing permission. It is one half of a pair, and the other half is a diagnosis that the trial population actually had. A two-year-old with a proven POMC deficiency and a fourteen-year-old who wants to lose weight before a school dance are not covered by the same sentence.

Under 12, and how many teenagers are actually prescribed these

No obesity medicine is approved for ordinary obesity below age 12. A 56-week trial of liraglutide in 82 children aged 6 to 11 cut BMI by 5.8 percent against a 1.6 percent rise on placebo. In 2023, after guidelines changed, prescribing among US adolescents with obesity rose about 300 percent, to 0.5 percent.

Below twelve, the evidence is arriving faster than the approvals. The SCALE Kids trial randomised 82 children aged 6 to under 12 with obesity to liraglutide or placebo for 56 weeks on top of lifestyle intervention, and reported a mean BMI change of minus 5.8 percent on the drug against plus 1.6 percent on placebo, an estimated difference of 7.4 percentage points [10]. Its own opening line is the regulatory status in one sentence: "No medications are currently approved for the treatment of nonmonogenic, nonsyndromic obesity in children younger than 12 years of age" [10]. The Wegovy label says the same thing from the other direction, listing use in patients under 12 among the things whose safety and effectiveness "have not been established" [5].

Twelve is also the age at which the pediatricians' own guidance changed. In January 2023 the American Academy of Pediatrics released a clinical practice guideline recommending that clinicians offer obesity medications, including GLP-1 receptor agonists, to adolescents aged 12 and older with obesity, as an adjunct to health behaviour and lifestyle treatment [11]. What happened next is the most useful number here for anyone who assumes teenagers are handed these injections freely. A CDC analysis of ambulatory medical records covering 526,973 US adolescents aged 12 to 17 with obesity found that the proportion prescribed an approved obesity medication rose from 0.1 percent in 2020 to 0.5 percent in 2023, a relative increase of roughly 300 percent and an absolute one of less than half a percentage point [11]. Of those who were prescribed something in 2023, 57.1 percent received semaglutide, and 83 percent of all prescriptions went to adolescents with severe obesity [11]. Prescribing was about twice as common among girls as boys and among 15-to-17-year-olds as 12-to-14-year-olds [11].

Those figures describe a cautious system. The label opened a door in 2022, the guideline pointed at it in 2023, and one in two hundred eligible adolescents walked through it, mostly those with the most severe disease [11]. That is the real bar: a clinician, a diagnosis the label covers, and a decision most clinicians are still making slowly. Our semaglutide course and liraglutide course go through what these trials measured and what they did not.

The vials sold online have no age because they have no patient

Research-use-only labels exist to deny that a human will take the product, so no age can be attached. The FDA treats the label as void when a website shows the product is meant for people. Federal law on human growth hormone punishes the distributor, and doubles the maximum sentence when the person involved is under 18.

Many of the peptides sold online, BPC-157 and the growth-hormone secretagogues among them, come in a third box that is not really a box at all. The vial says "for research only" or "not for human use" [16]. Taken at face value, that sticker says the contents are not for human use [16], and a product with no intended patient has nowhere to put an age. The Food and Drug Administration (FDA) has been explicit about how it reads those stickers. In a December 2025 warning letter to a vendor trading as Pinnacle Peptides, over selective androgen receptor modulators it sold with the same labelling, the agency wrote that despite the "FOR RESEARCH ONLY" and "NOT FOR HUMAN USE" statements, the firm's own website established that the products were intended to be drugs for human use, and were therefore unapproved new drugs [16].

The same enforcement wave reached the weight-loss peptides. On 9 September 2025 the FDA told an online seller called GLP-1 Solution that its compounded retatrutide products were unapproved new drugs and misbranded, because retatrutide has no approved application, no pharmacopeial monograph and no place on either compounding list [14]. The agency's public guidance says plainly that retatrutide and cagrilintide cannot be used in compounding under federal law, and lists among the red flags of an illegitimate seller a company that "does not require a screening and prescription by a licensed doctor" before shipping [15]. A seller who asks no doctor asks no age, and a product with no approved label has no line for one.

There is a federal statute about a peptide hormone that mentions an age, and it is aimed at the seller rather than the buyer. Under 21 U.S.C. 333(e), knowingly distributing human growth hormone, defined as somatrem, somatropin or an analogue of either, for any use in humans other than an authorised treatment on a physician's order carries up to five years in prison; where the offence involves an individual under 18 years of age, the maximum rises to ten years, and the Drug Enforcement Administration is authorised to investigate [13]. That is Congress writing the age of the buyer into the sentence of the seller. Note the definition, though. The statute defines human growth hormone as somatrem, somatropin or an analogue of either [13], so the secretagogues that prompt your own pituitary to release it are not named in it [13].

Why the age question is a medical question first

The pediatric labels report side effects that differ from adults: more gallstones, low blood pressure and hives on semaglutide, more vomiting and hypoglycemia on tirzepatide. Growth hormone treatment in children is a specialist decision for defined growth-failure diagnoses. Adolescence is when these hormone systems are still being set.

Everything above is law and labels. The reason regulators bother with an age at all is that children are not small adults, and the pediatric sections of the labels say so in their own numbers. Adolescents on Wegovy had greater incidences of cholelithiasis, cholecystitis, hypotension, rash, and urticaria (gallstones, gallbladder inflammation, low blood pressure, rash and hives) than adults on the same drug [5]. Children on Mounjaro had adverse reactions similar to adults "with the exception of a higher incidence of vomiting, abdominal pain, and hypoglycemia" [7]. In the Saxenda adolescent trial, one treated patient had pancreatitis, more episodes of confirmed hypoglycemia occurred on the drug than on placebo, and resting heart rate rose by a mean of 3 to 7 beats per minute [6]. None of that argues against the approvals. Each age on those labels came with a trial that reported these differences [5] [6] [7], and a product with no trial has no such number to show you.

The growth-hormone family raises the stakes further, because a growing body is the one thing an adult body is not. When pediatric endocrinologists use growth hormone or IGF-1 in children, they do it under guidelines written for specific diagnoses of growth failure, namely growth hormone deficiency, idiopathic short stature and primary IGF-1 deficiency, with recommendations graded against the evidence for each [17]. That is a specialist decision about a child whose growth has measurably gone wrong. We could find no equivalent trial of a growth-hormone secretagogue bought online in a healthy fifteen-year-old, and no vendor's "18+" checkbox substitutes for one. Our guide to whether peptides fit your situation at all covers the sport rules as well, which matter for junior athletes too.

What this means depending on who is asking

Under 18, the only lawful and evidence-backed route to a peptide medicine is a clinician working from a label that covers your diagnosis. A parent should treat "research use only" as the warning it is. An adult should read 18 as a contract threshold, not a safety rating, and check state law.

If you are under 18, the practical answer is simple even though the legal one is messy. Among the weight and blood-sugar peptides, the ones with evidence in people your age, the four on this page included, are tied without exception to a diagnosis and a prescriber, and the youngest ages on their labels (2, 4, 10 and 12) are conditions for a doctor, not a menu [5] [6] [7] [8]. Everything sold to you without a doctor carries no age because it carries no patient, and the FDA's view is that the research label on it is a marketing device, not a safety category [16]. In New York it is now unlawful for a store to sell a weight-loss or muscle-building supplement to anyone under 18 [1].

If you are a parent, the useful thing to know is that the system is slower than the internet makes it look. Half a percent of adolescents with obesity were prescribed an approved medicine in 2023, most of them with severe disease, and the guideline that opened that door came from the pediatricians' own academy [11]. A teenager who wants one can be walked to a clinician who will apply those rules. A vial that arrived by post with a research sticker and no prescription bypassed every one of them, and the one age law we found that touches that transaction was written for the seller [13].

If you are an adult, treat 18 as what it is: the age at which most states let you sign a binding contract, and in three states that age is 19 or 21 [3]. It did not change what is in the vial, which is why our guide to reading a certificate of analysis exists, and it did not turn an unapproved product into an approved one, the subject of our list of every FDA-approved peptide. Inside the prescription box the age question has a clean answer. Outside it, the honest reply is that nobody checked, and that is the problem rather than the permission.